Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Researchers at Stanford have invented a novel hydrogel with enhanced retention and extended durability. This hydrogel can be held together three times longer than many alternatives without sacrificing its self-healing attributes during injection.